Background: Drug-eluting stents(DES) are superior to bare metal stents to decreasing restenosis and need for revascularization. However, widespread utilization of DESs raises concerns with regard to risks of prolonged antiplatelet theraphy, late adverse events such as late stent thrombosis. Vessel diameter and lesion length are strong predictor for restenosis for DES and BMS. We have compared the restenosis rate and MACE(major cardiac adverse event) between DES and BMS in larger coronary artery(over 3.0mm). Method: This study assessed in stent restenosis(ISR), the long term outcomes(cardiac death,acute myocardiac infarction, and need for repeat interventoin in the treated vessel) of patients treated with either DES or BMS of ���3.5mm diameter. Between January 2003 and July 2007, we enrolled 300 consecutive patients who underwent DES implantation and those were angiographically and clinically followed for 1 year and compared to 300 patients who were treated with BMS. Exclusion criteria is cardiogenic shock, chronic total occlusion, in single vessel two stents. Two groups (DESs and BMSs) were compared in lesion length, reference diameter, post MLD(minimal luminal diameter)and follow up MLD. Primary end point is ISR and late loss at 6-9 month and secondary end point is MACE at 12 month. Result: Clinical charicteristics of DES and BMS are comparable. Most enrolled patients were men(71%) with single(45%) or two(33%) vessel disease. LAD lesion in 31%, RCA lesion in 44%. BMSs and DESs has equivalent reference vessel diameter(3.00짹0.5mm BMS vs 2.97짹0.48 p=0.4 DES). ISR is no significant change between wo groups(BMS 9%,DES 7%) MACE at 12 months is no different (BMS 8.7%, DES 7%) Conclusion: Implantation of DES in large coronary arteries confers no additional benefit compared with BMS and equal favorable outcomes at 12 months.